{"organizations": [], "uuid": "4ba394a5c6184f24de90d2fe43196fe014c02937", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abarca-amgen-enter-outcomes-based/brief-abarca-amgen-enter-outcomes-based-agreement-for-repatha-idUSFWN1QC18U", "country": "US", "domain_rank": 408, "title": "BRIEF-Abarca, Amgen Enter Outcomes-Based Agreement For Repatha", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T19:32:00.000+02:00", "replies_count": 0, "uuid": "4ba394a5c6184f24de90d2fe43196fe014c02937"}, "author": "", "url": "https://www.reuters.com/article/brief-abarca-amgen-enter-outcomes-based/brief-abarca-amgen-enter-outcomes-based-agreement-for-repatha-idUSFWN1QC18U", "ord_in_thread": 0, "title": "BRIEF-Abarca, Amgen Enter Outcomes-Based Agreement For Repatha", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "amgen", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "repatha reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 33 PM / Updated 28 minutes ago BRIEF-Abarca, Amgen Enter Outcomes-Based Agreement For Repatha Reuters Staff 1 Min Read Feb 22 (Reuters) - Amgen Inc: * ‍ABARCA SAYS SIGNED OUTCOMES-BASED CONTRACT WITH AMGEN FOR CHOLESTEROL-LOWERING DRUG, REPATHA​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-22T19:32:00.000+02:00", "crawled": "2018-02-22T19:51:27.023+02:00", "highlightTitle": ""}